BRPI0916601A2 - método e kit de diagnóstico de uma doença neurodegenerativa, e uso de um anticorpo que se liga a glutaminil ciclase (qc) ou uma isoforma da mesma - Google Patents

método e kit de diagnóstico de uma doença neurodegenerativa, e uso de um anticorpo que se liga a glutaminil ciclase (qc) ou uma isoforma da mesma

Info

Publication number
BRPI0916601A2
BRPI0916601A2 BRPI0916601A BRPI0916601A BRPI0916601A2 BR PI0916601 A2 BRPI0916601 A2 BR PI0916601A2 BR PI0916601 A BRPI0916601 A BR PI0916601A BR PI0916601 A BRPI0916601 A BR PI0916601A BR PI0916601 A2 BRPI0916601 A2 BR PI0916601A2
Authority
BR
Brazil
Prior art keywords
isoform
diagnosing
binds
antibody
kit
Prior art date
Application number
BRPI0916601A
Other languages
English (en)
Inventor
Astrid Kehlen
Hans-Ulrich Demuth
Jens-Ulrich Rahfeld
Martin Kleinschmidt
Monique Bornack
Stephan Schilling
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41256108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0916601(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of BRPI0916601A2 publication Critical patent/BRPI0916601A2/pt
Publication of BRPI0916601B1 publication Critical patent/BRPI0916601B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0916601-7A 2008-07-31 2009-07-31 Método de diagnóstico de doença de alzheimer (da), neurodegeneração em síndrome de down (nsd) ou comprometimento cognitivo leve (mci) em um indivíduo BRPI0916601B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8515408P 2008-07-31 2008-07-31
US61/085,154 2008-07-31
PCT/EP2009/059951 WO2010012828A2 (en) 2008-07-31 2009-07-31 Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases

Publications (2)

Publication Number Publication Date
BRPI0916601A2 true BRPI0916601A2 (pt) 2015-11-10
BRPI0916601B1 BRPI0916601B1 (pt) 2021-05-25

Family

ID=41256108

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916601-7A BRPI0916601B1 (pt) 2008-07-31 2009-07-31 Método de diagnóstico de doença de alzheimer (da), neurodegeneração em síndrome de down (nsd) ou comprometimento cognitivo leve (mci) em um indivíduo

Country Status (15)

Country Link
US (3) US20100028918A1 (pt)
EP (1) EP2329274B1 (pt)
JP (1) JP5677297B2 (pt)
KR (1) KR101682728B1 (pt)
CN (2) CN103983787A (pt)
AU (1) AU2009275869B2 (pt)
BR (1) BRPI0916601B1 (pt)
CA (1) CA2731933A1 (pt)
EA (1) EA025107B1 (pt)
IL (1) IL210266A (pt)
MX (1) MX2011001093A (pt)
NZ (1) NZ590658A (pt)
SG (1) SG193148A1 (pt)
WO (1) WO2010012828A2 (pt)
ZA (1) ZA201100177B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101433A1 (en) * 2010-02-18 2011-08-25 Probiodrug Ag Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase
SG194770A1 (en) 2011-05-27 2013-12-30 Probiodrug Ag Radiolabelled glutaminyl cyclase inhibitors
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
CN104946680A (zh) * 2015-06-11 2015-09-30 深圳大学 用于表达qc的重组载体及其制备方法、引物、基因工程菌
KR102362919B1 (ko) * 2016-07-08 2022-02-16 아지노모토 가부시키가이샤 경도 인지 장해 또는 알츠하이머형 인지증의 평가 방법
KR102858457B1 (ko) * 2023-06-07 2025-09-11 계명대학교 산학협력단 Ccl8 단백질 또는 이를 코딩하는 유전자를 유효성분으로 포함하는 퇴행성 뇌질환 진단용 바이오마커 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4374316B2 (ja) * 1993-01-25 2009-12-02 武田薬品工業株式会社 β−アミロイドまたはその誘導体に対する抗体およびその用途
JP3590468B2 (ja) * 1996-01-22 2004-11-17 財団法人 東京都医学研究機構 アルツハイマー病診断薬
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CN1784220B (zh) * 2003-05-05 2011-08-03 前体生物药物股份公司 谷氨酰胺酰基和谷氨酸环化酶效应物的应用
BRPI0415409A (pt) * 2003-10-15 2006-12-05 Probiodrug Ag uso de efetuadores de ciclases de glutaminila e glutamato
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
CA2554809C (en) * 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
US7592467B2 (en) * 2005-04-11 2009-09-22 Probiodrug Ag Inhibitors of prolyl endopeptidase
EP1865326B1 (en) * 2006-06-08 2011-09-07 FU Berlin Assay for the diagnosis of Alzheimer's Disease based on the determination of the ratio of secretase Aß cleavage products
EA016584B1 (ru) * 2006-09-21 2012-06-29 Пробиодруг Аг Новые гены, родственные гену глутаминилциклазы
WO2008087197A1 (en) * 2007-01-19 2008-07-24 Probiodrug Ag In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders

Also Published As

Publication number Publication date
CN102112880A (zh) 2011-06-29
EP2329274B1 (en) 2015-12-02
IL210266A (en) 2016-04-21
ZA201100177B (en) 2012-02-29
CN102112880B (zh) 2014-06-25
US20150247180A1 (en) 2015-09-03
BRPI0916601B1 (pt) 2021-05-25
HK1155813A1 (en) 2012-05-25
WO2010012828A2 (en) 2010-02-04
JP5677297B2 (ja) 2015-02-25
SG193148A1 (en) 2013-09-30
US20170097365A1 (en) 2017-04-06
MX2011001093A (es) 2011-03-15
CN103983787A (zh) 2014-08-13
AU2009275869A1 (en) 2010-02-04
EP2329274A2 (en) 2011-06-08
EA201100253A1 (ru) 2011-10-31
WO2010012828A3 (en) 2010-05-06
KR20110049781A (ko) 2011-05-12
IL210266A0 (en) 2011-03-31
JP2011529571A (ja) 2011-12-08
KR101682728B1 (ko) 2016-12-05
AU2009275869B2 (en) 2015-05-21
EA025107B1 (ru) 2016-11-30
CA2731933A1 (en) 2010-02-04
NZ590658A (en) 2012-07-27
US20100028918A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
BRPI0916601A2 (pt) método e kit de diagnóstico de uma doença neurodegenerativa, e uso de um anticorpo que se liga a glutaminil ciclase (qc) ou uma isoforma da mesma
BR112012019475A8 (pt) uso de um anticorpo monoclonal anti-cd44, anticorpo monoclonal anti-cd44, anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra
DK1831699T3 (da) Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme
BRPI0822033A2 (pt) Composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, kit
BRPI0821600A2 (pt) Composição farmacêutica, artigo de fabricação, kit de partes, método de combater aterosclerose, ou uma doença cardiovascular associada à aterosclerose, e, uso de um anticorpo
BR112012027147A2 (pt) método in vitro destinado à liberação de um composto de vitamina d e à medição de um composto de vitamina d, composição e mistura de reagente, uso de uma composição de reagente e kits
BR112014013082A2 (pt) método para detectar adutos nucleossomos
EP2294399A4 (en) INTEGRATED MULTISENSOR FOR NON-DESTRUCTIVE TEST PROCEDURES
BRPI0923199B8 (pt) método para determinar a presença de anticorpos de fixação de complemento
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
EP2056828A4 (en) SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS
BR112012016992A2 (pt) "funcionalidade que se liga a uma interface de contato assimétrico de um recpetor de tirosina quinase (rtk), hibridoma, composição farmacêutica, uso de uma quantidade efixaz da funcionalidade, método para identificar uma funcionalidade que se liga a uma interface de contato assimétrico de um receptor de tirosina quinase (rtk), e, molécula pequena".
WO2008106648A3 (en) Immunoassays exhibiting a reduction in prozone phenomena
BR112017023726A2 (pt) detecção de fatores de virulência microbiana na cavidade oral
BRPI0914925A2 (pt) peptídeo cíclico, uso de um peptídeo, métodos para produzir um peptídeo cíclico e para diagnosticar uma doença ou condição, e, anticorpo
EP2002459A4 (en) IMPROVED DETECTOR MODEL FOR CHARGED PARTICLE BEAM INSTRUMENT
DK2080012T3 (da) Fremgangsmåder til analyse af testforbindelser på forbundne receptorer.
BRPI0714642A2 (pt) "sequências do primer diagnóstico de tsv isolado, par de duas sequências do primer diagnóstico de tsv difenrentes, kit para detecção do tsv, métodos para a detecção da presença do tsv em uma amostra e método para q quantificação da quantidade de tsv em uma amostra"
BRPI0814471A2 (pt) Preparação de anticorpo, método para produzir a preparação de anticorpo, composição farmacêutica, kit de partes, e, uso de uma preparação de anticorpo
BR112012033163A2 (pt) ''anticorpos monoclonais, linhagens celulares, usos de um anticorpo, kit, métodos para detectar um anticorpo, composição de anticorpo e uso de uma composição de anticorpo''
BRPI0814346A2 (pt) Uso de imidazoquinolinas para o tratamento de doenças dependentes de egfr ou doenças que adquiriram resistência a agentes que são direcionados aos membros da família de egfr.
BR112013000340A2 (pt) anticorpo isolado que se liga a neuropilina-1 (nrp1), ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado e método de detecção da presença de nrp1 em uma amostra biológica
BRPI0607323A2 (pt) composições e uso de polipeptìdeos e kits para a detecção de anticorpo que se liga especificamente a um polipeptìdeo
BR112014009223A8 (pt) método para o diagnóstico da doença de niemann-pick
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.2 NA RPI NO 2608 DE 29/12/2020 POR TER SIDO INDEVIDA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: VIVORYON THERAPEUTICS AG (DE)

B25D Requested change of name of applicant approved

Owner name: VIVORYON THERAPEUTICS N.V. (DE)